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Abstract 70 
Non-alcoholic fatty liver disease (NAFLD) is a common disease, closely associated with obesity and 71 
insulin resistance. We investigated the presence of a subset of myeloid cells associated with metabolic 72 
disturbance in the liver of patients with NAFLD and a murine model of obesity-induced liver disease. 73 
Gene and protein expression in liver and serum was investigated with rt-PCR or ELISA and correlated 74 
to clinical disease. Liver-infiltrating immune cells were isolated from normal or diseased human liver 75 
for flow cytometric analysis. In animal experiments, mice were fed a high-fat diet (60% of calories 76 
from fat) for 16 weeks, or high-fat diet with 30% fructose for 32 weeks to induce steatohepatitis and 77 
fibrosis. A small molecule inhibitor of CCR2, CCX872, was administered to some mice. A subset of 78 
CD11c+CD206+ immune cells were enriched in human liver tissue, and greater infiltration was 79 
observed in NAFLD. The presence of CD11c+CD206+ myeloid cells correlated with systemic insulin 80 
resistance. CD11c+CD206+ cells expressed high levels of CCR2, and liver CCL2 expression was 81 
increased in NASH and correlated with disease activity. In mice, CCR2 inhibition reduced infiltration 82 
of liver CD11b+CD11c+F4/80+ monocytes, which are functional homologs of human CD11c+CD206+  83 
cells, and improved liver injury and glycaemic control. A role for CCR2/CCL2 in human NAFLD has 84 
long been postulated. These data confirm a role for this chemokine/receptor axis, through mediating 85 
adipose and hepatic infiltration of myeloid cells. Inhibition of CCR2 improved hepatic inflammation 86 
and fibrosis in murine models of NAFLD. These data confirm the rationale for targeting CCR2 to 87 
treat NAFLD.  88 
  89 
New and noteworthy 90 
These data show for the first time that CD11c+CD206+  myeloid cells, previously associated with 91 
human adipose tissue inflammation, infiltrate into liver tissue in non-alcoholic fatty liver disease. These 92 
cells express CCR2. Inhibition of CCR2 in mice inhibits hepatic inflammation caused by a murine 93 
homolog of these myeloid cells and improves experimental liver disease.  94 
 95 
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Disease 106 
Non-alcoholic fatty liver disease (NAFLD) covers a spectrum of liver pathology from hepatic 107 
steatosis (non-alcoholic fatty liver, NAFL) through the more severe non-alcoholic 108 
steatohepatitis (NASH) to cirrhosis (31). NAFLD is present in up to one-third of individuals 109 
(6) and is associated with the metabolic syndrome, particularly obesity (31) and insulin 110 
resistance (3). NAFLD is becoming the commonest indication for liver transplantation in the 111 
USA (32) reflecting both the prevalence of the disease and the present lack of 112 
effective therapies for advanced disease (25).  113 
There is increasing interest in the role of the innate immune system in obesity and the 114 
metabolic syndrome. Myeloid cells infiltrate adipose and liver tissue in patients with NAFLD 115 
and secrete cytokines and adipokines that contribute to insulin resistance and inflammation. 116 
In particular, CD11c+CD206+ monocytes in human adipose tissue are associated with 117 
adipocyte necrosis, inflammation and insulin resistance (30). In mice, a functionally similar 118 
subset defined by CD11b+CD11c+F4/80+ contribute to adipose inflammation and systemic 119 
insulin resistance in mice (22, 26). CCR2 mediates obesity-associated macrophage 120 
infiltration of adipose and hepatic tissue (19, 29). Mouse experiments have demonstrated 121 
that obesity increases hepatic expression of CCL2 (13, 14, 23, 29) and 122 
CD11b+CD11c+F4/80+ express CCR2 (26). Inhibition of the CCR2/CCL2 axis reduces 123 
disease activity in mice (21, 27, 33)(4, 8). The CCR2/CCL2 axis in human NAFLD is less 124 
well defined, although increased circulating levels of CCL2 are observed (12, 14). We 125 
investigated the inflammatory infiltrate in human NAFLD and murine models of obesity-126 
induced liver disease to determine whether functionally important subsets of CCR2 127 
inflammatory cells are involved in the metabolic dysfunction that characterises NAFLD.  128 
Materials and methods 129 
Human tissue  130 
Human tissue and blood was collected from patients with liver disease or healthy controls at 131 
University Hospitals Birmingham NHS Foundation Trust with full informed consent and 132 
research ethics committee approval (REC reference 06/Q2708/11). Liver tissue was 133 
obtained from patients undergoing hepatic resection for benign or malignant disease, or liver 134 
transplantation for chronic liver disease. In the case of hepatic resection, liver tissue distal to 135 
resected lesions was used for analysis. No patient had undergone chemotherapy in the two 136 
weeks prior to surgery. Liver tissue was placed in formalin or snap frozen prior to 137 
subsequent analysis. Characteristics of these groups and of patients undergoing resection or 138 
transplantation as a source of liver tissue are detailed in table 1. Serum from patients with 139 
NAFLD was obtained from 2 cohorts of patients taking part in the LEAN and NOBLES 140 
studies. LEAN is a randomised controlled trial of liraglutide in patients with NAFLD (2). The 141 
serum samples used were taken before randomisation. NOBLES is an observational study of 142 
biomarkers in patients with liver disease. Finally, a group of healthy volunteers without liver 143 
disease donated blood for analysis and served as a control group in ELISA experiments. This 144 
group were drawn from laboratory colleagues and gave consent for their samples to be used 145 
for research. 146 
Enzyme Linked Immunosorbent Assays (ELISA) 147 
Analysis of human serum was performed using commercially available ELISA kits. Serum 148 
CCL2 concentration was measured using R&D Systems Quantikine kits (Minneapolis, 149 
Minnesota USA, catalogue number PDCP00), performed according to the manufacturer’s 150 
instructions. Recombinant human chemokines were used as a positive control (Peprotech, 151 
New Jersey USA). Samples were diluted in sample buffer 1:4 and run in duplicate. A standard 152 
curve was generated from known concentrations of recombinant chemokine and 153 
experimental values interpolated from this curve. 154 
 155 
Polymerase Chain Reaction 156 
RNA was isolated by homogenizing liver tissue in Trizol (Life Technologies, California, USA). 157 
Chloroform was added and samples centrifuged at top speed in a microfuge for 15 minutes. 158 
The upper aqueous layer was removed, isopropanol was added and samples centrifuged at 159 
12,000rpm for 15 minutes. The resulting RNA pellet was washed in 70% ethanol and re-160 
suspended in nuclease free water. Purity and concentration of total RNA was determined 161 
spectrophotometrically. cDNA was prepared from RNA using Taqman reagents (Life 162 
Technologies, California, USA) according to the manufacturer’s instructions. Briefly, 2 μL of 163 
RNA was combined with random hexamers, reverse transcriptase, RNase inhibitor, 164 
magnesium chloride and a buffer solution. This mixture was heated to 25°C for 10 minutes, 165 
37°C for 30 minutes, 95°C for 5 minutes and then cooled to 4°C. Probe/primer mixes for 166 
genes of interest and appropriate controls were obtained from Taqman (Life Technologies, 167 
California, USA) and made up with Taqman reagents. A 96 well plate was used for reactions, 168 
with wells containing cDNA, primer/probe mix (CCL2 primer/probe mix catalogue number 169 
Hs00234140_m1, 18S mix catalogue number Hs03003631_g1) and Taqman mastermix. 170 
Three replicates were used for both the gene of interest and housekeeping gene. 18S has 171 
been shown to have lowest level of variability across stages of alcoholic liver disease (ALD) 172 
suggesting it is reliable as a housekeeping gene in steatohepatitis (5). PCR experiments were 173 
performed using a Roche Lightcycler 480 machine. A single quantification measurement was 174 
taken during each cycle.   175 
Isolation of leukocytes  176 
Isolation of leukocytes from human liver or blood 177 
Mononuclear cells were isolated from blood or liver. Liver was washed with phosphate 178 
buffered saline (PBS) to remove blood and digested non-enzymatically using GentleMACS 179 
(Miltenyi). The resulting homogenate was passed through a sterile 70 micron mesh . The 180 
homogenate was then washed in PBS until a clear supernatant was achieved. Liver 181 
homogenate or whole blood was layered over a density gradient (Lypmhoprep, CedarLane 182 
Labs, Canada) to isolate mononuclear cells, which were aspirated from the interface and 183 
washed in PBS three times before further analysis. 184 
Isolation of leukocytes from murine liver tissue 185 
Mice were sacrificed by CO2 inhalation and cervical dislocation. Blood samples were taken 186 
by left ventricular puncture. PBS was gently infused into the left ventricle to flush end organs 187 
of blood before harvesting. The liver were removed, immediately divided and placed into 188 
RPMI, formalin or snap frozen in liquid nitrogen. To isolate leukocytes, a segment of liver 189 
was coarsely chopped with scissors before mechanical dissociated by gently passing 190 
homogenate through a 75-micron sieve. The resulting homogenate was washed in PBS until a 191 
clear supernatant was achieved. For analysis of mouse liver, whole homogenate was 192 
incubated with fluorescently-tagged antibodies as described below, and CD45 used to 193 
identify leukocytes. 194 
Flow Cytometry analysis of leukocytes 195 
Isolated cells were suspended in 100μL at 1x106 cells/ml in MACS buffer (PBS containing 2% 196 
FCS and 1mM EDTA) and incubated with antibodies. After incubation for 20 minutes at 197 
room temperature, cells were washed and re-suspended in PBS and analysed by flow 198 
cytometry using a Beckman Coulter Cyan. Cells stained with single colours were analysed 199 
for compensation and appropriate isotype controls were used to define the negative 200 
populations.  201 
Animal experiments 202 
Mouse experiments were performed at ChemoCentryx Inc, California, USA. C57/Bl6 mice 203 
were purchased from Charles River, USA, and were housed in the research locations for at 204 
least three days before investigations were started. Animals were housed according to local 205 
and national standards. Animal housing was maintained at 23°c with twelve hour light/dark 206 
cycles. Male C57/Black 6 (C57/Bl6) mice bred in controlled clean conditions were used for 207 
all experiments, aged 6-8 week at the start of experiments.  208 
Two animal models were used: high fat diet (HFD) to induce steatohepatitis, or HFD in 209 
combination with 30% fructose in drinking water to induce steatohepatitis with fibrosis. The 210 
HFD provided 60% of calories from fat (by overall weight, this is provided 31% by lard and 211 
3% by soybean oil).  HFD and control diet were obtained from Teklad, USA. HFD was 212 
administered for 16 weeks; HFD+fructose was administered for 32 weeks. In each case, a 213 
control group of littermates were fed control diet (10% of calories from fat) with normal 214 
drinking water for the duration of the experiment. At the end of experiments mice were 215 
sacrificed by CO2 inhalation. 216 
Chemokine receptor antagonism 217 
A small molecule inhibitor of CCR2 (CCX872) manufactured by ChemoCentryx Inc, 218 
Mountain View, USA. CCX872 was dissolved in 1% hydroxypropyl methylcellulose (HPMC) 219 
and administered to mice by subcutaneous injection at a dose of 30mg/kg daily. An 220 
equivalent volume of 1% HPMC was given in control experiments. A maximum volume of 221 
350μL was used. 222 
Triglyceride content of murine liver tissue 223 
Triglyceride content of murine liver tissue was assessed using a commercially available 224 
colorimetric assay kit (Cayman Chemical Company, Ann Arbor MI USA) according to the 225 
manufacturer’s instructions. In short, 400mg of liver tissue was suspended in 2ml of assay 226 
diluent and homogenised. 10μl of homogenate was added to wells of a 96 well plate, each 227 
sample was assayed in triplicate. Triglycerides were enzymatically hydrolysed to free fatty 228 
acids and glycerol using the supplied enzyme mixture. After 15 minutes incubation colour 229 
change was measured with a plate reader (Synergy HT, BioTek, Vermont, USA) by 230 
measuring absorbance at 540nm. A standard curve was generated by assaying known 231 
concentrations of triglyceride and the triglyceride concentration of samples interpolated 232 
from this curve and expressed as milligram per gram of liver tissue.  233 
Fibrosis content of liver tissue 234 
Entire lobes of mouse livers were immersed in formalin immediately after harvesting and 235 
subsequently embedded in paraffin. Sections of10 μm thickness were stained with Sirius red 236 
(Sigma Aldrich, Missouri, USA) to detect collagen deposition. Briefly, sections were dewaxed 237 
and stained with haematoxylin before being stained with Sirius red for 1 hour. Sections were 238 
then dehydrated and mounted. Fibrosis was quantified by calculating percentage area of 239 
collagen deposition using Image-J software (National Institutes of Health, USA; version 1.48). 240 
Two Sirius red-stained slides per animal were taken at different depth, with 18 images taken 241 
randomly per slide for a total of 36 images per animal for collagen quantification. All 242 
pathologic evaluations were made by a pathologist on a random and blinded basis.  243 
Glycaemic control 244 
Glucose metabolism in mice was assessed with insulin and glucose challenge experiments. 245 
Insulin challenge was performed by administering 0.75U/kg of insulin (Sigma Aldrich, USA) to 246 
non-fasted mice via intra-peritoneal injection. Plasma glucose was measured with an 247 
AccuCheck glucometer (Roche, Basel, Switzerland) using a drop of blood from a tail vein. 248 
Plasma glucose was measured at baseline and 15, 30, 60, 90 and 120 minutes following 249 
administration of insulin. Mice were fasted overnight before glucose tolerance tests. Glucose 250 
(Sigma Aldrich, USA) was administered at 2g/kg of glucose (as 45% glucose solution), given 251 
by gastric lavage. Plasma glucose was measured at baseline and 15, 30, 60, 90 and 120 252 
minutes after administration of glucose using an AccuCheck glucometer and drops of blood 253 
from tail vein. 254 
Statistical Analysis 255 
Data are expressed as mean and SEM for normally expressed data, and median and 256 
interquartile range (IQR) for skewed data. Normality was assessed with the Kolmogorov-257 
Smirnov test. Normally distributed data were compared between groups with student’s t-258 
test, and the Mann-Whitney test used for skewed data. Variance across multiple groups, for 259 
example over a range of concentrations was analysed with one-way analysis of variance 260 
(ANOVA). Survival analysis was analysed by Kaplan-Meier curves with p values assessed with 261 
log-rank test. Median time to death in animals that died was also calculated. All authors had 262 
access to the study data and reviewed and approved the final manuscript. Data were 263 
analysed using Prism version 5 (California, USA). 264 
Results 265 
CD14+CD11c+CD206+ monocytes are enriched in NAFLD liver tissue  266 
Immune cells that express CD14+CD11c+CD206+ have been detected in human adipose 267 
tissue and associated with insulin resistance (30). We examined the presence of these cells 268 
in human blood and liver. Liver tissue from patients with NAFLD (n=8), other liver disease 269 
(ALD n=4, PSC n=3, PBC n=2, cryptogenic cirrhosis n=1, haemochromatosis n=1) or 270 
without liver disease (n=5) was analysed. Very few CD14+CD11c+CD206+ were observed in 271 
peripheral blood, whereas these cells were enriched in liver tissue (figure 1). The frequency 272 
of intrahepatic CD11c+CD206+ monocytes, as a percentage of CD45+CD14+ cells, differed 273 
significantly between types of liver disease (Kruskal-Wallis p=0.023) with highest frequency 274 
of cells seen in NAFLD (figure 1E). Mean fluorescence intensity (MFI) of CD11c and 275 
CD206 showed a tendency to be greater in NAFLD, although this did not reach statistical 276 
significant (Kruskal-Wallis p=0.056) (figure 1F). No differences in expression of CD11c and 277 
CD206 were seen between non-cirrhotic and cirrhotic liver tissue (data not shown). 278 
CD14+CD11c+CD206+ monocytes are associated with insulin resistance and express CCR2 279 
in NAFLD 280 
A correlation between the proportion of intrahepatic CD14+CD11c+CD206+ monocytes 281 
and glycosylated haemoglobin (HbA1c) was observed in liver infiltrating monocytes isolated 282 
from patients with chronic liver disease (r2 0.499 p=0.0005) (figure 2A). No significant 283 
correlation was observed with age, BMI or ALT (table 2). In both blood and liver, CCR2 284 
expression was largely restricted to CD14+ monocytes particularly the classical 285 
CD14++CD16- subset (figure 2B). The overall frequency of CCR2+ cells in blood or liver 286 
tissue did not vary significantly by aetiology of liver disease (one-way ANOVA p=0.236). 287 
However, CCR2+ expression on CD14+CD11c+CD206+ monocytes was higher in NAFLD 288 
compared to normal liver tissue or non-NAFLD liver disease in terms of the percentage of 289 
CD14+CD11c+CD206+ cells that expressed CCR2 (figure 3A) and the MFI of CCR2 290 
(figure 3B). 291 
CCL2 is upregulated in NAFLD  292 
CCL2 gene expression in liver tissue was analysed by quantitative real-time PCR using 18S as 293 
a housekeeping gene. CCL2 gene expression was significantly up regulated in liver tissue from 294 
patients with NAFLD undergoing transplantation (Mann Whitney test p=0.009) (figure 4A).  295 
The concentration of CCL2 was measured by ELISA in serum of individuals with biopsy-296 
proven NAFLD (n=20) or healthy volunteers (n=10). Serum CCL2 concentration was 297 
significantly higher in patients with NAFLD compared to healthy volunteers (median 298 
305.1pg/ml (IQR 211.8 – 385.7) vs. 224.7 (105.2 – 255.4), Mann-Whitney test p=0.021) 299 
(figure 4B). NAFLD was assessed histologically by independent pathologists using the 300 
NAFLD activity score (NAS) proposed by Kleiner and Brunt (15). Serum CCL2 301 
concentration was higher in individuals with more severe histological inflammation (assessed 302 
with the NAFLD activity score (NAS) (15))(one way ANOVA p=0.025) but levels did not 303 
correlate with fibrosis stage (one way ANOVA p=0.347) (figure 4C, D). When 304 
individual components of the NAS were considered, serum CCL2 concentration was 305 
associated with higher lobular inflammation score (one-way ANOVA p=0.043) but not with 306 
steatosis or hepatocyte ballooning, consistent with the known role of CCL2 as a monocyte 307 
chemo-attractant.  308 
Inhibition of CCR2 reduces accumulation of F4/80+CD11c+ monocytes in murine 309 
steatohepatitis 310 
CD11b+ CD11c+F4/80+ monocytes are found in adipose tissue in experimentally induced 311 
obesity in mice, and are functionally similar to CD11c+CD206+ monocytes in humans. To 312 
investigate the effect of CCR2 inhibition in obesity-induced steatohepatitis, twenty-six male 313 
C57/Bl6 mice were given HFD with 60% of calories from fat for 16 weeks. After eight weeks 314 
of HFD, the mice were divided into two groups: thirteen were treated daily with CCX872 315 
(30mg/kg/day, administered by subcutaneous injection) and 13 received an equivalent volume 316 
of vehicle (1% HPMC). A further 8 littermates were given control diet for the duration of 317 
the experiment. 318 
Steatosis, assessed by measuring triglyceride content of liver tissue, was markedly increased 319 
after 16 weeks of HFD. Mice treated with CCX872 had significantly less triglyceride 320 
accumulation in comparison with vehicle treated mice (169.6mg/g ±21.20 vs. 284.2 ±31.9, 321 
student’s t-test p=0.007) with levels reduced to those seen in animals receiving a control 322 
diet (figure 5A). Serum ALT was significantly lower in CCX872-treated mice (mean ALT 323 
252.5IU/ml ±56.02 vs. 532.8 ±98.07, student’s t-test p=0.028) (figure 5B).  The reduction in 324 
hepatic steatosis was confirmed histologically (figure 5C) but histological features of 325 
inflammation and fibrosis did not differ between groups (figure 5D, E).  326 
Flow cytometric analysis of isolated liver-infiltrating immune cells revealed an increase in 327 
CD11b+F4/80low cells in all HFD fed mice. No differences were seen between groups with 328 
regard to intrahepatic frequencies of CD11b+F4/80hi Kupffer cells or overall CD11b+F4/80low 329 
infiltrating monocytes (figure 6A, B). However, fewer CCR2 expressing monocytes were 330 
seen in CCX872 treated mice (figure 7A) and CCR2 inhibition reduced liver infiltration 331 
with Ly6chi monocytes (figure 7B). HFD feeding resulted in higher intrahepatic and adipose 332 
tissue frequencies of CD11b+ CD11c+F4/80+ cells, an immune cell population functionally 333 
similar to CD11c+CD206+ cells in humans which are implicated in the development of 334 
obesity mediated insulin resistance (19). The frequency of CD11b+CD11c+F4/80+ cells in 335 
both adipose and liver tissue was significantly reduced after treatment with CCX872 (figure 336 
6C, D).  337 
Inhibition of CCR2 reduces scarring in murine steatohepatitis and fibrosis 338 
Only mild hepatic fibrosis was seen after 16 weeks of HFD (figure 7E). As fibrosis is an 339 
important prognostic marker in human NAFLD (1, 9) we sought to assess the effects of 340 
CCR2 antagonism on the development of fibrosis. Fructose intake is associated with more 341 
severe fibrosis in human NAFLD (24) and has been shown to cause fibrosis in animal models 342 
of NAFLD (7, 16). We used HFD and fructose to induce fibrosis and assess the effect of 343 
CCR2 antagonism. Twenty-two mice were given HFD and 30% fructose for 32 weeks. 344 
CCX872 or vehicle was administered daily for the final eight weeks of the experiment, each 345 
to 11 mice. A further four littermates were given control diet for the duration of the 346 
experiment. 347 
Consistent with initial experiments, after 32 weeks lower ALT concentrations were 348 
observed in CCX872-treated animals (median 67.0 IU/L vs. 251.5IU/L, p<0.006 by Mann 349 
Whitney test) although interestingly, lower than seen after a shorter period of HFD diet 350 
alone. Hepatic fibrosis, assessed by area of scarring on histology, was significantly reduced in 351 
the livers of mice receiving CCX872 (mean area 0.83 % (SD 0.22) vs. 2.01 (1.5), p=0.01 by 352 
student’s t-test) (figure 8).  353 
CCR2 antagonism improves glucose metabolism in mice given HFD 354 
At the start of the treatment period (after eight weeks of HFD), response to a glucose load 355 
was similar between CCX872 and vehicle treated mice (figure 9A, C). However, after 8 356 
weeks of treatment there was a significant improvement in response of CCX872 mice 357 
compared to vehicle treated mice (AUC 48545 mg/dl/min vs. 31795 mg/dl/min, student’s t-358 
test p<0.001) (figure 9B, C). Insulin challenge was performed by administering a standard 359 
dose of 0.75units/g of insulin by intra-peritoneal injection to non-fasted mice. At the start of 360 
the treatment period changes in plasma glucose concentration in response to insulin were 361 
similar in both groups of mice fed HFD (figure 9D, F). After a further 8 weeks of HFD and 362 
treatment with CCX872 or vehicle, there was a significant difference between groups (AUC 363 
21719 mg/dl/min vs. 16553 mg/dl/min, student’s t-test p<0.001) (figure 9D,F).  364 
Discussion 365 
Non-alcoholic fatty liver disease is a common condition closely related to obesity and the 366 
metabolic syndrome. Progressive disease is typified by hepatic inflammation in the form of 367 
steatohepatitis and fibrosis (11). We report here that a subset of monocytes that express 368 
both CD11c and CD206 are enriched in the liver of patients with NAFLD and their 369 
presence is associated with insulin resistance.  A similar subset has been reported previously 370 
in human adipose tissue but not in liver tissue (30). We show that intrahepatic 371 
CD11c+CD206+ monocytes express CCR2, and it principal ligand, CCL2, is over-expressed 372 
in NAFLD liver tissue suggesting that the CCR2/CCL2 axis may promote trafficking of 373 
CD11c+CD206+ monocytes to the liver in NAFLD which would suggest targeting CCR2 374 
therapeutically may be of benefit in NAFLD.  375 
 376 
To test this hypothesis we investigated the role of CCR2 in trafficking of pro-inflammatory 377 
myeloid cells in a mouse model of non-alcoholic fatty liver disease where high fat diet feeding 378 
causes insulin resistance, steatohepatitis and hepatic fibrosis. When a small molecule 379 
inhibitor of CCR2 was administered to mice the numbers of liver and adipose tissue 380 
infiltrating CD11b+CD11c+F4/80+ cells was reduced, accompanied by improvements in liver 381 
histology and glycaemic control.  382 
 383 
The transition from simple steatosis to NASH is associated with hepatic inflammation and 384 
the development of insulin resistance even in the absence of overt diabetes mellitus. The 385 
present study suggests that a specific subset of liver tissue infiltrating monocytes provide the 386 
link between hepatic inflammation and insulin resistance. Wentworth at el. reported that the 387 
presence of pro-inflammatory CD11c+CD206+ monocytes in subcutaneous and omental 388 
adipose tissue of obese individuals (30) was associated with insulin resistance.  This was 389 
mediated in part through the inhibition of the action of insulin on adipocytes. We now 390 
report the same subset of monocytes in the livers of patients with NASH.  In contrast to 391 
Wentworth we detected high levels of CCR2 on CD11c+CD206+ cells in the liver. A 392 
comparable subset of monocytes in mice is defined by F4/80 and CD11c expression.  These 393 
cells express CCR2 and use it to infiltrate adipose tissue (19). Our data confirm and extend 394 
these observations by showing that pharmacological inhibition of CCR2 reduces not only 395 
adipose tissue infiltration but also hepatic infiltration by this subset.  A crucial role for these 396 
cells in disease pathogenesis was suggested by our finding of a strong correlation between 397 
the frequency of CD11c+CD206+ cells in the liver and clinical measurement of insulin 398 
resistance. Thus local hepatic insulin resistance may be mediated in part through 399 
inflammation caused by this monocyte subset recruited to the liver in response to increased 400 
CCL2 expression. Thus, the improvement in glucose metabolism observed in mice is likely to be 401 
multi-factorial. Improved adipose tissue inflammation will improves insulin resistance at this site, 402 
while reduced hepatic inflammation is also likely to improve hepatic glucose metabolism. 403 
 404 
There have been several studies that examine the CCR2/CCL2 axis in the murine models of 405 
liver disease Inhibition of CCR2/CCL2 either through genetic manipulation (23, 29) or 406 
pharmaceutical targeting (4, 17, 21, 27, 33) leads to improvements in steatosis, 407 
inflammation or fibrosis with variation dependent on the model employed. Many of 408 
these pre-clinical pharmaceutical studies have relied on transgenic mice (28, 33) used 409 
non-physiological methods such as administration of carbon tetrachloride (4) or 410 
streptozotocin (17), or deficient diets (4, 21) and as such are of limited translational value. 411 
Our data presented here deliberately used diets that mimic high-fat and /or high-412 
carbohydrate diets which are a feature of human liver disease. This is a particular contrast to 413 
the study by Lefebvre et al (17) who induced NASH in part by using streptotozin to kill 414 
pancreatic islet cells.  415 
 416 
Increased CCL2 expression in human NAFLD has been described previously by Haukeland 417 
et al. (12) who reported higher levels of circulating CCL2 in NAFLD and in progressive 418 
disease. Our data confirm this finding and by correlating CCL2 blood levels with histological 419 
features seen on liver biopsies taken at the same time show that CCL2 expression 420 
correlates with hepatic inflammation but not fibrosis. We also show increased liver-specific 421 
expression of CCL2 in patients with NAFLD although this data has limitations through the 422 
number of samples used for analysis of liver-specific CCL2 expression, and the necessary 423 
reliance of samples from patients with advanced disease to analyse liver inflammation.  CCL2 424 
is the major chemokine ligand for the receptor CCR2 which mediates myeloid cell trafficking 425 
into tissues. Intrahepatic monocytes as a group express low levels of CCR2 but this is not 426 
the case for CD11c+CD206+ monocytes which maintain high levels of CCR2 suggesting that 427 
CCL2/CCR2 interactions may be more important for the recruitment and positioning of 428 
these cells in liver tissue. Based on these findings we hypothesised that inhibiting CCR2 429 
would reduce transmigration of monocytes into adipose and liver tissue. This was confirmed 430 
in mice where inhibition of CCR2 using a small molecule CCR2 inhibitor reduced 431 
accumulation of the corresponding murine subset of monocytes associated with reduced 432 
steatohepatitis and improved metabolic parameters. Several studies have reported on the 433 
use of a variety of pharmaceutical inhibitors of CCR2 in murine fatty liver disease, 434 
administered in a variety of routes and in a variety of disease models (21, 27, 33). The 435 
human data presented here confirm that CCR2 antagonism may be of benefit in 436 
NAFLD and indeed a phase II trial of a joint CCR2/CCR5 inhibitor, cencriviroc, 437 
reported in 2016 showing benefit on hepatic fibrosis (10). The recently published results of 438 
the dual CCR2/CCR5 inhibitor, cencriviroc, in clinical NAFLD show some changes in 439 
inflammatory activity and encouraging improvements in fibrosis compared to placebo treatment. 440 
The most obvious difference between CCX872 and cencriviroc is the additional effect on CCR5 441 
which may bring additional benefits in the setting of liver disease. Interestingly when cenicriviroc 442 
was compared to CCX872 in the methinone-choline deficient diet model of steatohepatitis, 443 
greater improvement in ALT and fibrosis was observed with CCX872 (20), although the MCD is 444 
not noted for causing a great deal of fibrosis and also lacks relevance to human NAFLD. CCR2 445 
antagonists have been used in clinical trials in a variety of diseases where their use seems 446 
safe. Treatment of NAFLD would likely require administration over at least months and 447 
possibly years, and as such long-term safety is important. One important aspect of long-term 448 
use is the impact of CCR2 inhibition on carcinogenesis. Any effects are difficult to predict at 449 
present as animal models yield conflicting data (18), and CCR2 inhibition is being trialled for 450 
use in for example pancreatic cancer. 451 
 452 
In conclusion, we suggest that a particular subset of monocytes is associated with 453 
progressive disease non-alcoholic fatty liver disease and that infiltration of liver by this subset 454 
is driven at least in part by CCL2/CCR2 signalling. Inhibition of this axis in NAFLD may be a 455 
rational means of improving hepatic and adipose tissue inflammation to prevent progressive 456 
liver disease. 457 
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 549 
Table 1: characteristics of cohorts used for human studies 550 
 
Age 
Years 
BMI 
Kg/m2 
ALT 
IU/L 
Diabetes 
prevalence 
Serum 
NOBLES 55.1 33.9 56.1 58% 
LEAN 51.0 36.0 71.5 33% 
Liver tissue 
NASH cirrhosis 56.9 32.7 37.5 88% 
non-NASH cirrhosis 55.3 29.3 34.1 14% 
Normal 57.5 27.3 20.0 0% 
 551 
Table 2: correlation of frequency of intrahepatic CD11c+CD206+ monocytes with clinical 552 
parameters 553 
 
Correlation with intrahepatic  CD11c+CD206+ monocytes 
(as % of CD14+)  
(r2) 
p value 
HbA1c 0.50 <0.001 
ALT 0.02 0.551 
BMI 0.04 0.388 
Age 0.16 0.084 
 554 
 555 
Figure legends 556 
 557 
Figure 1: CD11c+CD206+ monocytes are enriched in liver tissue. A, B gating strategy to 558 
identify CD45+CD14+ monocytes. Representative samples of (C) peripheral blood and (D) 559 
liver infiltrating monocytes from the same individual (E). Liver tissue from patients with 560 
NAFLD (n=8) showed a greater proportion of CD11c+CD206+ monocytes as a proportion 561 
of CD45+CD14+ monocytes, compared to other chronic liver disease (ALD n=4, PSC  =3, 562 
PBC n=2, haemochromotosis n=1, cryptogenic cirrhosis n=1) or normal liver (n=5) (*p<0.05 563 
by Kruskal-Wallis). (F) Mean fluorescence intensity of CD11c+CD206+ cells by liver disease 564 
(Kruskal-Wallis p=0.056). 565 
 566 
Figure 2: Monocytes were isolated from liver tissue from patients with or without NAFLD 567 
and analysed by flow cytometry. A The frequency of CD11c+CD206+ monocytes in liver 568 
tissue correlated with insulin resistance, measured by HbA1c. n=24, r2 = 0.499. B CCR2 569 
percentage expression was greater on CD14++CD16- monocytes with a non-significant 570 
reduction of CCR2 expression on all intra-hepatic monocytes. 571 
 572 
Figure 3: Monocytes were isolated from liver tissue and analysed by flow cytometry.  CCR2 573 
expression was higher on CD11c+CD206+ monocytes isolated from NAFLD liver tissue 574 
(n=8) compared to non-NAFLD cirrhosis (n=11) or normal liver tissue (n=5) with regard to 575 
A percentage of CCR2+cells (normal, median 39.4% IQR 40.1, non-NAFLD cirrhosis 59.7% 576 
IQR 24.9, NAFLD 80.1% IQR 24.7) and mean fluorescent intensity (normal 171 IQR 163.7, 577 
non-NAFLD cirrhosis 200.6 IQR 80.1, NAFLD 3299 IQR 144.4). Data shown as median and 578 
IQR, n=23 in each case. *p<0.05 by Mann-Whitney test 579 
  580 
581 
Figure 4: A RNA was isolated from liver tissue and CCL2 gene expression analysed by 582 
semi-quantitative PCR. CCL2 gene expression was significantly increased in liver tissue from 583 
patients with NASH (n=6) compared to normal liver tissue (n=6) (Mann Whitney test 584 
p<0.01). B Serum concentration of CCL2 measured by ELISA was higher in NAFLD (n=20) 585 
compared to healthy volunteers (n=10) (Mann Whitney test p<0.05) C serum concentration 586 
of CCL2 increased with increasing disease activity as measured by the NAS score (one way 587 
ANOVA p<0.05) D no relation was seen with fibrosis stage (one way ANOVA p>0.05)  588 
 589 
Figure 5: Improvements in steatohepatitis with inhibition of CCR2. Thirteen animals in each 590 
group were given HFD with daily administration of vehicle or CCX872, and a further 8 591 
animals were given a control diet for 16 weeks. Triglyceride content was measured with a 592 
colorimetric assay. CCR2 inhibition reduced triglyceride accumulation (*p<0.05, **p<0.01 by 593 
students t-test). B CCR2 inhibition reduced serum ALT  (*p<0.05 by student’s t-test). 594 
Histological assessment of liver disease confirmed reduced steatosis, as assessed by area of 595 
staining, panel C, but no differences in D histological inflammation or E histological fibrosis  596 
 597 
Figure 6: Myeloid cells from liver and adipose tissue from mice given a high fat diet were 598 
analysed by flow cytometry. Treatment with a small molecule inhibitor of CCR2 did not 599 
affect proportions of A intrahepatic Cd11b+F4/80hi Kupffer cells or B overall infiltrating 600 
CD11b+F4/80low monocytes (Mann-Whitney test to compare vehicle and CCX872 groups, 601 
*p>0.05). CCR2 antagonism reduced infiltration of CD11c+F4/80+ cells into C liver tissue 602 
(Mann-Whitney test to compare vehicle and CCX872 groups, * p<0.05) and D adipose 603 
tissue (Mann-Whitney test to compare vehicle and CCX872 groups, t-test p<0.05). Data are 604 
shown as boxes to denote IQR with line at median and whiskers showing maximum and 605 
minimum values.  606 
 607 
Figure 7: Myeloid cells from liver and adipose tissue from mice given a high fat diet 608 
were analysed by flow cytometry. Treatment with a small molecule inhibitor of CCR2 609 
reduced hepatic infiltration with CCR2+ CD11b+F4/80lo monocytes (student’s t-test 610 
p<0.05) and B infiltration of liver tissue by pro-inflammatory Ly6chi cells (**p<0.05 by 611 
student’s t-test)   612 
 613 
Figure 8: 22 C57/Bl6 mice were fed HFD with 30% fructose in drinking water, or control 614 
diet without fructose, for 32 weeks. CCR2 antagonism with a small molecule inhibitor, 615 
CCX872, reduced fibrosis compared to vehicle control. Representative pictures of liver 616 
sections from A control and B CCX872-treated animals. C Fibrosis as assessed by 617 
percentage collagen area by Sirius red staining of liver sections. Data are shown as mean and 618 
SEM **p<0.05 by student’s t-test 619 
 620 
Figure 9: CCR2 antagonism improved glycaemic control in mice on a HFD with CCR2. 621 
Glycaemic control was assessed at the beginning and end of the treatment period 622 
with glucose tolerance tests and insulin challenges. Mice in each group were showed 623 
similar responses at the start of the treatment period (A, D). At the time of sacrifice 624 
mice treated with CCX872 showed significantly improved response to glucose and 625 
insulin (B, E). When assessed by measuring area under the curve statistically 626 
significant changes were seen (C, F). ***p<0.001 by student’s t-test. 627 
 628 
 629 
 630 
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 633 
 634 
 635 
 636 
 637 
Downloaded from www.physiology.org/journal/ajpgi by ${individualUser.givenNames} ${individualUser.surname} (147.188.108.163) on March 15, 2018.
Copyright © 2018 American Physiological Society. All rights reserved.
A B CCR2 expression - %
CD14++CD16- CD14++CD16+ CD14-CD16++
0
20
40
60
80
100
Liver
Blood
%
 C
C
R
2+
Frequency of CD11c+CD206+ by HbA1c 
0 10 20 30 40 50 60 70
0
10
20
30
40
50
HbA1c (mmol/mol)
%
  o
f C
D
45
+ C
D
14
+ 
ce
lls
Downloaded from www.physiology.org/journal/ajpgi by ${individualUser.givenNames} ${individualUser.surname} (147.188.108.163) on March 15, 2018.
Copyright © 2018 American Physiological Society. All rights reserved.
Normal liver Non-NAFLD cirrhosis NAFLD
0
20
40
60
80
100
%
 C
C
R
2+
*
*
A B
Normal liver Non-NAFLD cirrhosis NAFLD
0
100
200
300
400
500
M
FI
*
*
Downloaded from www.physiology.org/journal/ajpgi by ${individualUser.givenNames} ${individualUser.surname} (147.188.108.163) on March 15, 2018.
Copyright © 2018 American Physiological Society. All rights reserved.
0-1 2-3 4-5 6-8
0
50
100
150
200
250
300
350
400
450
500
550
pg
/m
l
*
A B
C D
F0 F1 F2 F3 F4
0
100
200
300
400
500
pg
/m
L
Healthy NAFLD
0
100
200
300
400
500
pg
/m
L
*
Normal liver NASH
0
2
4
20
40
60
80
100
fo
ld
 c
ha
ng
e 
frm
o 
av
er
ag
e 
of
 n
or
m
al
**
Downloaded from www.physiology.org/journal/ajpgi by ${individualUser.givenNames} ${individualUser.surname} (147.188.108.163) on March 15, 2018.
Copyright © 2018 American Physiological Society. All rights reserved.
Lobular inflammation
Vehicle CCX872
0.0
0.5
1.0
1.5
2.0
2.5
in
fla
m
m
at
or
y 
cl
us
te
rs
/2
0x
 fi
el
d
Histology: steatosis by area
Vehicle CCX872
0
20
40
60
%
 a
re
a
Fibrosis by area
Vehicle CCX872
0.0
0.1
0.2
0.3
0.4
0.5
%
 a
re
a
C D E
HFD: Liver triglyceride content
Control diet Vehicle CCX872
0
100
200
300
400
500
m
g/
g
***
A B
Alanine aminotransferase
Control diet Vehicle CCX872
0
200
400
600
800
U
/L
*
Downloaded from www.physiology.org/journal/ajpgi by ${individualUser.givenNames} ${individualUser.surname} (147.188.108.163) on March 15, 2018.
Copyright © 2018 American Physiological Society. All rights reserved.
Intrahepatic CD11c+F4/80+
Control Vehicle CCX872
0
20
40
60
80
100
%
 o
f C
D
11
b+
*
Adipose tissue CD11c+F4/80+
Control Vehicle CCX872
0
20
40
60
80
100
%
 o
f C
D
11
b+
*
C D
Intrahepatic resident Kupffer Cells
Control Vehicle CCX872
0
20
40
60
%
 o
f C
D
45
+
ns
Intrahepatic infiltrating monocytes
Control Vehicle CCX872
0
10
20
30
40
50
%
 o
f C
D
45
+
ns
A B
Downloaded from www.physiology.org/journal/ajpgi by ${individualUser.givenNames} ${individualUser.surname} (147.188.108.163) on March 15, 2018.
Copyright © 2018 American Physiological Society. All rights reserved.
Control Vehicle CCX872
0
20
40
60
80
100
%
 o
f C
D
11
b+
F4
/8
0l
o
CCR2+ infiltrating CD11b+F4/80lo monocytes
*
A B Intrahepatic Ly6chi monocytes
Control diet Vehicle CCX872
0
10
20
30
%
 o
f C
D
11
b+
F4
/8
0d
im **
**
Downloaded from www.physiology.org/journal/ajpgi by ${individualUser.givenNames} ${individualUser.surname} (147.188.108.163) on March 15, 2018.
Copyright © 2018 American Physiological Society. All rights reserved.
Downloaded from www.physiology.org/journal/ajpgi by ${individualUser.givenNames} ${individualUser.surname} (147.188.108.163) on March 15, 2018.
Copyright © 2018 American Physiological Society. All rights reserved.
Start of treatment glucose challenge
0 30 60 90 120
0
100
200
300
400
500
Control diet
Vehicle
CCX872
time (minutes)
m
g/
dL
End of treatment glucose challenge
0 30 60 90 120
0
100
200
300
400
500
Control
Vehicle
CCX872
time (minutes)
m
g/
dL
A
B
Glucose challenge pre-and post-treatment
Pre-treatment Post-treatment
0
10000
20000
30000
40000
50000
60000
Vehicle
CCX872
ns ***
m
g/
dL
/m
in
ut
e
C
End of treatment insulin challenge
0 30 60 90 120
0
50
100
150
200
250
300
Control
Vehicle
CCX872
time (minutes)
se
ru
m
 g
lu
co
se
 m
g/
dL
Start of treatment insulin challenge
0 30 60 90 120
0
50
100
150
200
250
300
Control diet
Vehicle
CCX872
time (minutes)
se
ru
m
 g
lu
co
se
 m
g/
dL
Insulin challenge pre- and post-treatment
Pre-treatment Post-treatment
0
10000
20000
30000
Vehicle
CCX872
***ns
m
g/
m
L/
m
in
ut
e
D
E
F
Downloaded from www.physiology.org/journal/ajpgi by ${individualUser.givenNames} ${individualUser.surname} (147.188.108.163) on March 15, 2018.
Copyright © 2018 American Physiological Society. All rights reserved.
